Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Phase 2 Completed N=14 Randomized Quadruple-blind Treatment

Amantadine to Speed Awakening After Cardiac Arrest

coma · Heart Arrest · Anoxia
Source: ClinicalTrials.gov NCT02486211 ↗
Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Dec 2019
Primary outcomePrimary: Rate of Awakening (Number of Patients Who Are Able to Follow Commands) — 2; 2 Participants

Summary

This study evaluates if amantadine will increase the rate of awakening in patients resuscitated from cardiac arrest but comatose (not following commands) after their resuscitation. Half of the participants will receive amantadine and the other will receive placebo.

Outcome Measures

OutcomeResultp-value
PRIMARY
Rate of Awakening (Number of Patients Who Are Able to Follow Commands)		 2; 2 —
SECONDARY
Time to Awakening		 4; 8 —
SECONDARY
Seizures (Number of Patients Who Experience Seizures as Detected by EEG Monitoring With or Without Clinical Correlate)		 0; 2 —
SECONDARY
Nausea or Vomiting		 0; 0 —
SECONDARY
Number of Participants With Severe or Intracranial Bleeding		 0; 0 —

Eligibility Criteria

Inclusion Criteria

  • Non traumatic cardiac arrest
  • Age 18 and older
  • Defibrillation and/or chest compressions by healthcare providers
  • Return of spontaneous circulation

Exclusion Criteria

  • Written do not attempt resuscitation (DNAR) reported to providers before randomization
  • Known prisoner or pregnancy
  • Lack of motor response to pain and absent N20 response on somatosensory evoked potentials prior to randomization
  • Initial CT demonstrating brain edema (defined as grey white ratio <1.2)
  • Presence of malignant pattern on EEG at time of randomization
  • Next of kin unwilling to provide supportive care for at least one week after enrollment
  • Presently using other dopaminergic agent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02486211). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search